Solid Biosciences Trial Gene Therapy on Hold by FDA

Solid Biosciences Inc. said on Tuesday the U.S. Nourishment and Drug Administration has put on hold a preliminary testing its quality treatment for a muscle-squandering issue.

A month ago one of the six patients with Duchenne solid dystrophy dosed with the organization’s medication, SGT-001, encountered a genuine symptom that was regarded identified with the treatment, the organization said.

Leave a Reply

Your email address will not be published. Required fields are marked *